ストックスクリーナーアプリを入手
0.697
0.58%
-0.0041
プレマーケット:
.70
0.003
+0.43%
前日終値:
$0.7011
開ける：
$0.704
24時間の取引高:
540.98K
Relative Volume:
0.71
時価総額：
$19.13M
収益：
-
当期純損益:
$-38.85M
株価収益率:
-0.2409
EPS:
-2.8936
ネットキャッシュフロー:
$-44.99M
1週間 パフォーマンス:
+25.77%
1か月 パフォーマンス:
-9.48%
6か月 パフォーマンス:
-50.21%
1年 パフォーマンス:
-0.85%
1日の値動き範囲:
$0.6612
$0.7127
1週間の範囲:
$0.505
$0.7127
52週間の値動き範囲:
$0.476
$2.48
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
名前
Citius Pharmaceuticals Inc
セクター
電話
(908) 967-6676
住所
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
0.697 | 19.25M | 0 | -38.85M | -44.99M | -2.8936 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-12-30 | アップグレード | D. Boral Capital | Hold → Buy |
| 2021-11-30 | 開始されました | Maxim Group | Buy |
Citius Pharmaceuticals Inc (CTXR) 最新ニュース
Citius Oncology Announces Presentation of LYMPHIR® Phase 1 Combination Study Data at the 2026 American Society of Clinical Oncology Annual Meeting – Company AnnouncementFT.com - Financial Times
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
TENK News & Events - Intellectia AI
Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants - Stock Titan
5 Best Rated Penny Stocks to Buy According to Wall Street Analysts - Insider Monkey
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances - Stock Titan
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026 - Intellectia AI
Citius Pharmaceuticals Price Target Announced at $4.00/Share by HC Wainwright & Co. - Moomoo
H.C. Wainwright Initiates Citius Pharmaceuticals(CTXR.US) With Buy Rating, Announces Target Price $4 - Moomoo
CTXR Assumes Buy Rating by HC Wainwright & Co. -- Price Target a - GuruFocus
Citius Pharmaceuticals (CTXR) price target increased by 20.00% to 6.12 - MSN
Citius Pharmaceuticals Q2 Net Income USD -21. - Moomoo
Is Citius Pharmaceuticals (CTXR) Undervalued After Q2 FY2026 Upd - GuruFocus
CTXR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Citius Pharmaceuticals reports $5.6M H1 revenue from LYMPHIR; Q2 net loss $21.2M - TradingView
CTXR: $5.6M in LYMPHIR revenue, 80% gross margin, $21.2M Q2 net loss, $41.5M new financing - TradingView
[8-K] CITIUS ONCOLOGY, INC. Reports Material Event - Stock Titan
Citius Pharmaceuticals Q2 revenue rises on LYMPHIR launch - TradingView
Citius Pharmaceuticals (CTXR) logs $5.6M LYMPHIR sales, deeper losses in Q2 2026 - Stock Titan
Citius Pharmaceuticals, Inc. 3Q FY2026: Revenue $1.67M, EPS $(0.95) — 10-Q Summary - TradingView
CTXR: LYMPHIR launch spurred revenue growth, but losses rose sharply due to a major contract termination - TradingView
Citius Oncology 2Q Loss/Shr 27c >CTOR - Moomoo
Citius Pharmaceuticals (CTXR) starts LYMPHIR sales but faces heavy loss and going concern risk - Stock Titan
Citius Oncology (NASDAQ: CTOR) flags going concern, adds $25.0 million loan - Stock Titan
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock - Quantisnow
CTXR Stock Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Pharmaceuticals secures $5M through equity offering - MSN
TradingKey - TradingKey
Number of shareholders of Citius Pharmaceuticals Inc – GETTEX:47N0 - TradingView
Citius Pharmaceuticals Announces Third Amendment to Promissory Note with Citius Oncology – SEC Filing Details - Minichart
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility - TipRanks
Citius Pharmaceuticals (CTXR) adds $0.90 share conversion to $3.8M note - Stock Titan
Citius Pharmaceuticals subsidiary raises up to 36.5 million dollars for LYMPHIR commercialization - Traders Union
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization – Company AnnouncementFT.com - Financial Times
Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR® Commercialization - PR Newswire
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Quantisnow
Citius Oncology (NASDAQ: CTOR) registers 6.82M warrant shares, updates LYMPHIR trials and launch - Stock Titan
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - Quantisnow
Citius Oncology sees first international shipment of LYMPHIR to Europe - ROI-NJ
CTXR Price Today: Citius Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Citius Expands LYMPHIR Access with First European Shipment - TipRanks
Citius Oncology Begins First European Expansion of LYMPHIR - TipRanks
Citius Pharmaceuticals (Nasdaq: CTXR) unit sends first LYMPHIR shipment to Europe - Stock Titan
Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network - MSN
Citius Oncology Ships First International Order of LYMPHIR™ to E - GuruFocus
Citius Pharmaceuticals expands LYMPHIR global reach with initial European shipment - Traders Union
Citius Oncology Ships First International Order of LYMPHIR™ to Europe - ChartMill
Citius Pharmaceuticals Inc (CTXR) 財務データ
収益
当期純利益
現金流量
EPS
0.98%
0.12%
大文字化:
|
ボリューム (24 時間):